The Israeli Biomed company Bonus Biogroup, announced Wednesday that it had implanted a bone graft in a leg of a patient suffering from a critical bone deficiency.
The bone graft was developed in the company’s lab from cells collected from fat tissue taken from the patient’s body. This is the first transplant in the world of this kind.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at email@example.com.
The transplant is carried out as part of a clinical trial conducted by the Company and in which three patients participate. In this experiment, examine orthopedic treatment in humans to complete a critical deficiency in bone limbs (hand or foot) using a live graft of human bone through injection.
In August 2017 the company reported an implantation of bone graft, also for the first time, in a patient’s forearm. Later, a similar transplant was performed in another patient.
This is Phase 1-2 of the clinical trial. Its objectives are to examine the safety and efficacy of second-generation bone-transplants using a BioGroup for the rehabilitation and recovery of bone in the body. The experiment is performed in the orthopedics of the Emek Hospital in Afula, led by Prof. Nimrod Rosen.
This is Phase 1-2 of the clinical trial. Its objectives are to examine the safety and efficacy of second-generation bone-transplants using the BioGroup bonus injection product for the rehabilitation and recovery of a bone on its own body. The experiment is performed in the orthopedic wards of Ha’emek Hospital in Afula, led by Prof. Nimrod Rosen.
The trial is planned to include 40 to 30 participants aged 18-75.
The bone graft is produced in the laboratory of the Bonus BioGroup in Haifa, in a unique growth system that simulates the conditions required for bone production in the human body – about two weeks after a sample of fat tissue from the intended patient was taken.
Fat tissue is separated into cells that are sorted into different types and from which the company collects the cells needed to produce human bone.
From these cells, Bonus produces a bone implant injection made from tiny bone granules. After implantation of an injection bone implant in the missing area of the patient’s body, the tiny bone particles unite into a solid, human bone, allowing full healing of the implantation area.
The company says it aims to offer the global market for bone reconstruction, estimated at $7.5 billion in 2017, the first of its kind in the world, safe and fast, to complete bone loss with only one injection of a live implant.
Prior to implantation of the bone graft in the current patient, two surgeries were performed to repair the bone of the leg, which was damaged in an accident. In these operations, a metal device is used to connect the bone parts of the leg. However, even after the two surgeries, there was a significant lack of bone in the leg, which did not allow full connection of the bone fracture, limited its activity, and there was even a constant fear of bone fracture. Under these circumstances, it was decided to implant the BioGroup-made bone graft